Another open-label multicenter Phase I trial (NCT02088112) has also been recently conducted to evaluate the combination of gefitinib and duvalumab in patients with EGFR-mutant and EGFR TKI-naïve NSCLC (127). This evidence concerns the gene EGFR and non-small cell lung carcinoma.